Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: A population-based cohort study

European Journal of Preventive Cardiology

Volumn 14, Issue 3, 2007, Pages 392-397

  Engström, Gunnar ^a   Hedblad, bo ^a   Janzon, Lars ^a   Lindgärde, Folke ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

C3; C4; complement; epidemiology; inflammation; myocardial infarction; stroke

Indexed keywords

CHOLESTEROL; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPLEMENT BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; COMPLEMENT C3; COMPLEMENT C4; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS;

EID: 34250649678     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000244582.30421.b2     Document Type: Article

References (31)

1. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 2004; 18: 1–8.
2. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 355: 1058–1066.
3. Gabrielsson BG, Johansson JM, Lönn M, Jernas M, Olbers T, Peltonen M, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res 2003; 11: 699–708.
4. Hoie EB, McGuire TR, Leuschen PM, Zach TL. Pentoxifylline inhibits tumor necrosis factor-alpha induced synthesis of complement component C3 in human endothelial cells. Biol Pharm Bull 2004; 27: 1670–1673.
5. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115–126.
6. Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert AK. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation 2000; 102: 2576–2581.
7. Oksjoki R, Kovanan PT, Pentikainen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol 2003; 14: 477–482.
8. Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, Carroll M, et al. Influence of C3 deficiency on atherosclerosis. Circulation 2002; 105: 3025–3031.
9. Niculescu F, Rus H. The role of complement activation in atherosclerosis. Immunol Res 2004; 30: 73–80.
10. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348–2354.
11. Yasojima K, Schwab C, McGeer EG, McGeer PL. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1214–1219.
12. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386–1392.
13. Speidl WS, Exner M, Amighi J, Kastl SP, Zorn G, Maurer G, et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005; 26: 2294–2299.
14. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti B, Drago G, et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 2000; 21: 1081–1090.
15. Onat A, Uzunlar B, Hergenc G, Yazici M, Sari I, Uyarel H, et al. Cross-sectional study of complement C3 as a coronary risk factor among men and women. Clin Sci (Lond) 2005; 108: 129–135.
16. Engström G, Hedblad B, Eriksson KF, Janzon L, Lindgärde F. Complement C3 is a risk factor for the development of diabetes. A population-based cohort study. Diabetes 2005; 54: 570–575.
17. Weyer C, Tataranni PA, Pratley RE. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000; 23: 779–785.
18. Engström G, Hedblad B, Janzon L, Lindgärde F. Weight gain in relation to plasma levels of complement C3. Results from a population-based cohort study. Diabetologia 2005; 48: 2525–2531.
19. Szeplaki G, Prohaszha Z, Duba J, Rugonfalvi-Kiss S, Karadi I, Kokai M, et al. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 2004; 177: 383–389.
20. Ajjan R, Grant PJ, Futers TS, Brown JM, Cymbalista CM, Boothby M, et al. Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb Haemost 2005; 94: 1048–1053.
21. Muscari A, Bozzoli C, Massaelli G, Puddu GM, Palareti G, Legnani C, et al. Complement components and fibrinogen: correlations and association with previous myocardial infarction. Cardiology 1995; 86: 232–237.
22. Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C, et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995; 98: 357–364.
23. Berglund G, Eriksson KF, Israelsson B, Kjellström T, Lindgärde F, Mattiasson I, et al. Cardiovascular risk groups and mortality in an urban Swedish male population: the Malmö Preventive Project. J Intern Med 1996; 239: 489–497.
24. Kristenson H, Trell E. Indicators of alcohol consumption: comparisons between a questionnaire (Mm-MAST), interviews and serum gamma-glutamyl transferase (GGT) in a health survey of middle-aged males. Br J Addict 1982; 77: 297–304.
25. Engström G, Hedblad B, Rosvall M, Janzon L, Lindgärde F. Occupation, marital status, and low-grade inflammation: mutual confounding or independent cardiovascular risk factors? Arterioscler Thromb Vasc Biol 2006; 26: 643–648.
26. Laurell CB. Electroimmuno assay. Scand J Clin Lab Invest Suppl 1972; 124: 21–37.
27. Engström G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgärde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 2002; 105: 2632–2637.
28. Yasojima K, Schwab C, McGeer EG, McGeer PL. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ Res 1998; 83: 860–869.
29. Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003; 1609: 127–143.
30. Van Harmelen V, Reynisdottir S, Cianflone K, Degerman E, Hoffstedt J, Nilsell K, et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 1999; 274: 18243–18251.
31. Butts WC, James GE, Keuhneman M. Intra-individual variation in the concentrations of IgA, IgG, IgM, and complement component C3 in serum of a normal adult population. Clin Chem 1977; 23: 511–514.